Efficacy and safety of aromatase inhibitors in early breast cancer.

Expert Opin Drug Saf

York University, 1115 Glen Eden Court, Pickering, Toronto, ON L1V6N8, Canada.

Published: September 2008

Background: Third-generation aromatase inhibitors (AIs) are surfacing as the standard adjuvant treatment for postmenopausal women with hormone receptor positive breast cancer over tamoxifen but their long-term effects are still under investigation.

Objective: In the light of current information, what factors should health practitioners take into consideration when prescribing AIs to patients?

Methods: Results of several randomized controlled adjuvant clinical trials were reviewed to assess the efficacy of treatment and their subprotocols focusing on quality of life and skeletal health to highlight the safety concerns.

Conclusion: To prevent early recurrences, AIs should be considered as the upfront hormonal treatment of choice. They are also recommended for use as a switching strategy after 2-3 years of tamoxifen and as extended adjuvant treatment after 5 years of tamoxifen. The adverse events experienced are manageable and overall quality of life is not compromised; however, bone density must be monitored for patients at risk and appropriate bone-protection supplements need to be taken.

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.7.5.547DOI Listing

Publication Analysis

Top Keywords

aromatase inhibitors
8
breast cancer
8
adjuvant treatment
8
quality life
8
years tamoxifen
8
efficacy safety
4
safety aromatase
4
inhibitors early
4
early breast
4
cancer background
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!